{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=73", "query": { "intervention": "Injectable Placebo", "page": 73 }, "page_size": 10 }, "pagination": { "page": 73, "page_size": 10, "total_count": 4220, "total_pages": 422, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=74&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=72&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T05:49:32.184Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04905212", "title": "A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy" ], "interventions": [ { "name": "Telitacicept 160mg", "type": "DRUG" }, { "name": "Telitacicept 240mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RemeGen Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-11-04", "completion_date": "2023-11-09", "has_results": false, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 8, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04905212" }, { "nct_id": "NCT04897412", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Subcutaneous Fat" ], "interventions": [ { "name": "CBL-514 Injection", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Caliway Biopharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 75, "start_date": "2022-02-14", "completion_date": "2023-03-22", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 4, "location_summary": "Chicago, Illinois • Omaha, Nebraska • Nashville, Tennessee + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04897412" }, { "nct_id": "NCT00423319", "title": "Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Deep Vein Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Enoxaparin-matching placebo", "type": "DRUG" }, { "name": "Apixaban-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5407, "start_date": "2007-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423319" }, { "nct_id": "NCT02407600", "title": "Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Vomiting", "Nausea", "Emesis" ], "interventions": [ { "name": "FOSAPREPITANT (Emend)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ajeet Gajra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2015-04", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2015-04-03", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407600" }, { "nct_id": "NCT00806819", "title": "Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nintedanib (BIBF1120)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "B12", "type": "DRUG" }, { "name": "dexamethasone (or corticosteroid equivalent)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2008-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 40, "location_summary": "Downy, California • Fountain Valley, California • Fullerton, California + 37 more", "locations": [ { "city": "Downy", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Meriden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806819" }, { "nct_id": "NCT00605475", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 231, "start_date": "2007-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2012-02-13", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "MD", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605475" }, { "nct_id": "NCT05683457", "title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Infection" ], "interventions": [ { "name": "mRNA-1647", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2023-04-05", "completion_date": "2027-03-06", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 3, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Seattle, Washington", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05683457" }, { "nct_id": "NCT00091130", "title": "SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Squamous Cells of Undetermined Significance", "Cervical Cancer", "High-grade Squamous Intraepithelial Lesion", "Low-grade Squamous Intraepithelial Lesion" ], "interventions": [ { "name": "HspE7", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 139, "start_date": "2004-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-03", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091130" }, { "nct_id": "NCT02065557", "title": "Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 101, "start_date": "2014-10-13", "completion_date": "2020-02-07", "has_results": true, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065557" }, { "nct_id": "NCT00725881", "title": "Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Intermittent Claudication" ], "interventions": [ { "name": "Trans sodium crocetinate (TSC)", "type": "DRUG" }, { "name": "0.9% normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diffusion Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 48, "start_date": "2008-08", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2011-07-29", "last_synced_at": "2026-11-03T05:49:32.184Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725881" } ] }